ADC Therapeutics SA (NYSE:ADCT) Stock Has Consensus Target Price of $5.00 According to Brokerages

Shares of ADC Therapeutics SA (NYSE:ADCT) have been given an average rating of “Hold” by the six analysts that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $5.00.

A number of research analysts recently weighed in on the stock. Guggenheim decreased their price target on shares of ADC Therapeutics to $5.00 and set a “buy” rating on the stock in a research note on Monday, August 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ADC Therapeutics in a research note on Friday, July 17th. Finally, Wall Street Zen upgraded ADC Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th.

ADC Therapeutics Stock Performance

NYSE:ADCT opened at $1.72 on Wednesday. The stock has a market capitalization of $218.95 million, a PE ratio of -2.60 and a beta of 1.86. ADC Therapeutics has a fifty-two week low of $0.78 and a fifty-two week high of $4.98. The company has a fifty day moving average of $1.17 and a two-hundred day moving average of $2.07.

ADC Therapeutics (NYSE:ADCT) last announced its earnings results on Thursday, August 13th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.11. The company had revenue of $19.25 million during the quarter, compared to analyst estimates of $18.89 million. Research analysts forecast that ADC Therapeutics will post -0.80 earnings per share for the current year.

Institutional Trading of ADC Therapeutics

Several large investors have recently made changes to their positions in the company. AXQ Capital LP acquired a new stake in ADC Therapeutics during the 2nd quarter worth $29,000. R Squared Ltd acquired a new position in ADC Therapeutics during the first quarter worth about $38,000. Quantinno Capital Management LP raised its holdings in ADC Therapeutics by 36.0% in the 1st quarter. Quantinno Capital Management LP now owns 14,719 shares of the company’s stock valued at $55,000 after acquiring an additional 3,894 shares during the last quarter. Revolve Wealth Partners LLC acquired a new stake in ADC Therapeutics in the 2nd quarter valued at about $107,000. Finally, Sei Investments Co. lifted its stake in ADC Therapeutics by 45.6% in the 1st quarter. Sei Investments Co. now owns 33,461 shares of the company’s stock worth $125,000 after purchasing an additional 10,472 shares in the last quarter. 41.10% of the stock is currently owned by hedge funds and other institutional investors.

About ADC Therapeutics

ADC Therapeutics SA (NYSE: ADCT) is a commercial-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for the treatment of cancer. Its ADC technology is designed to use antibodies to selectively deliver potent cytotoxic agents to cancer cells, with the goal of limiting exposure to healthy tissue.

The company’s lead product is Zynlonta (loncastuximab tesirine-lpyl), an ADC directed at the CD19 antigen. Zynlonta is approved in the United States for the treatment of adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.